

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

ALPHA JECT micro 6 emulsion for injection for Atlantic salmon

2. Composition

1 dose (0.05 ml) contains:

Active substances:

<i>Aeromonas salmonicida</i> , strain AL 2017, inactivated	$\geq 12.6 \log_2$ ELISA units
<i>Vibrio anguillarum</i> serotype O1, strain AL 112, inactivated	RPS ≥ 75 %
<i>Vibrio anguillarum</i> serotype O2a, strain AL 104, inactivated	RPS ≥ 75 %
<i>Aliivibrio salmonicida</i> , strain AL 1134, inactivated	RPS ≥ 90 %
<i>Moritella viscosa</i> , strain AL 266, inactivated	$\geq 10.7 \log_2$ ELISA units
Infectious pancreatic necrosis virus serotype Sp., strain AL V103, inactivated	0.12-0.28 AU

ELISA units: Serological response in Atlantic salmon.

RPS: Relative Percentage Survival in challenge studies on Atlantic salmon.

AU: Antigenicity Units (quantity of virus antigen measured in the final product).

Adjuvants: Paraffin, light liquid (mineral oil): 23 mg.

White to cream coloured emulsion.

3. Target species

Atlantic salmon of a minimum weight of 25 g.

4. Indications for use

For active immunisation of Atlantic salmon to reduce mortality caused by infections with *Aeromonas salmonicida* (furunculosis), *Vibrio salmonicida* (coldwater vibriosis), *Listonella anguillarum* serotype O1 and O2a (vibriosis), *Moritella viscosa* (winter sore) and IPNV (infectious pancreatic necrosis virus).

Onset of immunity: 520 degree days post vaccination for the bacterial antigens and 600 degree days post vaccination for IPNV.

Duration of immunity: 1 year for the bacterial antigens and 5.5 months for IPNV.

5. Contraindications

None.

6. Special warnings

Special warnings:

Vaccinate healthy animals only.

Special precautions for safe use in the target species:

Vaccination should preferably be performed at water temperatures of 15 °C or below.

Do not vaccinate at water temperatures below 3 °C or above 18 °C.

Avoid vaccination during smoltification.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to fish vaccines should avoid contact with the veterinary medicinal product.

Protective equipment consisting of guarded needles should be used during manual vaccination.

Ensure that the method of fixation and handling of the fish minimises the risk of accidental self-injection. Repeated self-injections may aggravate the adverse effects or increase the risk of anaphylactic shock.

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Fertility:

The potential effect of vaccination on spawning function has not been investigated.

Vaccination of broodfish should only be done according to a benefit-risk assessment by the responsible veterinarian/fish health biologist.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

Overdose:

Following administration of 0.1 ml of the vaccine (double dose) no other adverse reactions than those described in section "Adverse events" were seen.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

7. Adverse events

Atlantic salmon:

Very common (>1 animal / 10 animals treated):

- Adhesion (Speilberg score 1-2)
- Melanin accumulation¹

Common (1 to 10 animals / 100 animals treated):

- Adhesion (Speilberg score 3)

Very rare (<1 animal / 10 000 animals treated, including isolated reports):

- Adhesion (Speilberg score ≥ 4)

¹ In the abdominal cavity

The severity of adverse reactions may be influenced by different factors such as sanitation, vaccination technique, fish size at vaccination and water temperature during vaccination and in the first 6-12 weeks after vaccination. As a general precaution it is recommended to perform vaccination at water temperature of 15 °C or below. Small fish and high water temperature may increase the severity of adverse reactions.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system:

HPRA Pharmacovigilance

Website: www.hpra.ie

8. Dosage for each species, routes and method of administration

Dosage

Administer a single dose of 0.05 ml per fish. Fish should not be vaccinated more than once.

Administration route

The vaccine should be administered by intraperitoneal (i.p) injection into the midline about one fin length anterior to the base of the pelvic fin. It is recommended to starve the fish for a minimum of 48 hours before vaccination. The fish should be anaesthetised prior to injection.

9. Advice on correct administration

To reduce the risk of adverse reactions, it is important to deposit the entire dose in the abdominal cavity. The injection needle used should have appropriate length to penetrate the abdominal wall and 1 2 mm into the abdominal cavity.

Let the vaccine slowly reach 15-20 °C by keeping it at room temperature.

Ensure a homogenous emulsion prior to use by squeezing and shaking the vaccine bag for approx. 2 minutes. Only administer the vaccine if it appears as a homogenous, white to cream coloured emulsion after shaking. The vaccine should not be used if the vaccine shows signs of a brownish water phase in the bottom of the container. Contact the distributor for further advice.

The injection devices used for vaccination, i.e. automatic vaccination machines or manual syringes, must be designed and suitable for administration of the recommended dose volume in the target species. The devices must be operated by trained personnel and should be calibrated according to the manufacturers' recommendation prior to use. Special care should be taken to ensure air is removed from the injection equipment (chambers and tubes) prior to vaccination. Regular dose controls are recommended.

The vaccination equipment should be thoroughly cleaned / sterilized before use.

10. Withdrawal periods

Zero degree days.

11. Special storage precautions

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C - 8 °C).

Do not freeze. Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp.

Shelf life after first opening the immediate packaging: 10 hours.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

VPA 10804/005/001

Pack sizes:

Zip-lock bag with 1 x 250 ml or 500 ml vaccine bag, or cardboard box with 10 x 500 ml vaccine bag.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

07/2025

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

16. Contact details

Marketing authorisation holder, manufacturer responsible for batch release and contact details to report suspected adverse events:

PHARMAQ AS

7863 Overhalla

Norway

Tel: +47 23 29 85 00

E-mail: phq.phvig@zoetis.com

17. Other information

POM (Prescription Only)